Form 4: GeneDx Holdings Corp. Director Eli Casdin Reports Equity Transactions and RSU Grants

Eli Casdin, a Director and 10% Owner of GeneDx Holdings Corp., reported the acquisition of Class A Common Stock through RSU settlement and new RSU grants.

Summary

• Eli Casdin, a Director and 10% Owner of GeneDx Holdings Corp. (WGS), reported transactions on June 18, 2025, as detailed in a Form 4 filing.
• He acquired 12,924 shares of Class A Common Stock through the settlement of Restricted Stock Units (RSUs) at a price of $0.
• Concurrently, 12,924 Restricted Stock Units were disposed of, indicating their conversion into common stock.
• Mr. Casdin also received a new grant of 3,576 Restricted Stock Units (RSUs) at a price of $0.
• Following these transactions, Eli Casdin directly beneficially owns 20,518 shares of Class A Common Stock and 3,576 Restricted Stock Units.
• Indirect beneficial ownership includes 3,507,164 shares held by Casdin Partners Master Fund, L.P., 19,247 shares held by Casdin Partners GP, LLC, and 333,144 shares held by CMLS Holdings LLC, all of which Mr. Casdin may be deemed to indirectly beneficially own.

Sentiment

Score: 7

Explanation: The filing indicates a director and significant owner is increasing direct share ownership through RSU settlement and receiving new equity grants. While part of a compensation plan, this generally signals continued alignment and commitment to the company's performance.

Positives

• Acquisition of 12,924 Class A Common Stock shares by a director and 10% owner, Eli Casdin, through the settlement of Restricted Stock Units, increases his direct equity stake.
• Grant of 3,576 new Restricted Stock Units to Eli Casdin further aligns his interests with long-term shareholder value, as these units vest based on continued service.

Future Outlook

The newly granted Restricted Stock Units (RSUs) are scheduled to vest on the earlier of the next annual meeting of GeneDx Holdings Corp.'s shareholders following the grant date or the first anniversary of the grant date, contingent upon Eli Casdin's continued provision of services to the Issuer through each vesting date.

Industry Context

This Form 4 filing details routine insider equity transactions for a director and significant shareholder within the biotechnology and genomics sector. Such filings provide transparency into changes in management and large shareholder holdings, which can offer insights into their confidence in the company, though these specific transactions appear to be part of a standard equity compensation plan rather than discretionary open market purchases.

Related Party Transactions

• Eli Casdin's indirect beneficial ownership through Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC, and CMLS Holdings LLC indicates related party interests where he holds managing member or board positions, sharing voting and investment discretion.

Stakeholder Impact

• Shareholders: The filing provides transparency into the equity holdings and compensation structure of a key director and significant owner. The acquisition of shares through RSU settlement and the grant of new RSUs can be viewed positively as it aligns the director's financial interests with the company's performance and shareholder value.

Next Steps

• Vesting of the newly granted 3,576 Restricted Stock Units will occur on the earlier of the next annual meeting of shareholders or the first anniversary of the grant date, subject to Eli Casdin's continued service to GeneDx Holdings Corp.

Key Dates

Keywords

GeneDx Holdings Corp., WGS, Eli Casdin, Form 4, Insider Transaction, Beneficial Ownership, Restricted Stock Units, Equity Compensation, Director, 10% Owner